<DOC>
	<DOCNO>NCT01224665</DOCNO>
	<brief_summary>RATIONALE : Lymphadenectomy may remove tumor cell spread nearby lymph node patient invasive bladder cancer . It yet know whether extend pelvic lymphadenectomy effective standard pelvic lymphadenectomy surgery . PURPOSE : This randomized phase II trial study standard pelvic lymphadenectomy see well work compare extended pelvic lymphadenectomy treat patient undergo surgery invasive bladder cancer .</brief_summary>
	<brief_title>S1011 Standard Extended Pelvic Lymphadenectomy Treating Patients Undergoing Surgery Invasive Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To compare disease-free survival ( DFS ) patient muscle-invasive urothelial carcinoma bladder undergo radical cystectomy extend pelvic lymph node dissection ( PLND ) standard pelvic lymphadenectomy . Secondary - To compare overall survival ( OS ) patient randomize extended PLND versus randomize standard pelvic lymphadenectomy . - To evaluate operative time ; whether nerve sparing perform , intraoperative , peri-operative 90-day morbidity mortality ; length hospital stay ; histology ( pure urothelial versus mixed ) ; lymph node count lymph node density ; adjuvant chemotherapy receive ; local retroperitoneal soft tissue recurrence patient randomize extended PLND versus randomize standard pelvic lymphadenectomy . - To collect peripheral blood two paraffin-embedded block primary tumor translational medicine study , include circulate tumor cell ( CTCs ) markers epithelial mesenchymal transition , correlate finding pathologic T stage node metastasis well DFS OS . OUTLINE : This multicenter study . Patients stratify accord prior neoadjuvant therapy ( yes v ) , clinical stage ( T2 vs T3 v T4a ) , Zubrod performance status ( 0-1 v 2 ) . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo radical cystectomy standard pelvic lymphadenectomy . - Arm II : Patients undergo radical cystectomy extend pelvic lymphadenectomy . Blood tumor specimen may collect periodically translational study . After completion study therapy , patient follow periodically 6 year .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm urothelial carcinoma bladder Stage T2 , T3 , T4a disease No clinical stage consistent lowrisk node metastasis ( CIS , T1 ) No T4b disease ( fixed lesion ) Disease require primary radical cystectomy lymph node dissection definitive treatment No laparoscopic surgery Predominant urothelial carcinoma follow element allow : Adenocarcinoma Squamous cell carcinoma Micropapillary minor component rare phenotype No pure squamous cell carcinoma adenocarcinoma No visceral nodal metastatic disease proximal common iliac bifurcation 2view chest xray abdominalpelvic image computerized tomography MRI abdomen pelvis No intraoperative pelvic lymph node involvement ( confirm frozen section ) bifurcation common iliac vessel extend template PATIENT CHARACTERISTICS : Zubrod performance status 02 ALT AST ≤ upper limit normal ( ULN ) * Alkaline phosphatase ≤ ULN* Not pregnant nursing Fertile patient must use effective contraception No prior malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , stage I II cancer patient complete remission past 5 year Medically suitable undergo cystectomy , physician 's opinion NOTE : *Levels may ≥ ULN provide metastatic disease exclude use dedicate liver imaging , bone scan , biopsy . PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior partial cystectomy invasive bladder cancer No prior pelvic surgery would obviate complete extend lymphadenectomy ( e.g. , aortofemoral/iliac bypass ) Prior neoadjuvant chemotherapy cancer allow provide complete patient recover No prior pelvic irradiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>stage II bladder cancer</keyword>
	<keyword>stage III bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
</DOC>